SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan® Platform at Genomax’s Singapore lab

SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a global leader in proteomics technology, today announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. This effort is SomaLogic’s first grant in the APAC region. The winners of the award will receive proteomic data from SomaLogic’s 7,000-plex assay, which will be run at Singapore-based Molecular Genomics, a Genomax Technologies company. The Genomax site, opened in November 2022, was the first SomaLogic authorized site in Asia to offer the SomaScan® Platform.

The grant program, which was launched at the Asia Oceana Human Proteome Organisation (AOHUPO) meeting in Singapore, requires that researchers in academic, medical centers, pharmaceutical companies, and contract research organizations in life sciences, submit a proposal outlining how they will use the SomaScan Platform to expand their research goals in health or in a specific disease area. Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan Platform at Genomax’s Singapore lab. Researchers can apply on SomaLogic’s website: http://somalogic.com/genomaxgrant2023.

While experts across the region have long embraced the value of genomics, life science researchers in Asia are now increasingly appreciating the power and the promise of proteomics in their discovery efforts. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.

“Asia is an incredibly important and rapidly growing market because of their increasing focus on translational work in life sciences and clinical research,” said SomaLogic Chief Executive Officer Adam Taich. “We are excited to bring this inaugural grant program to researchers in Singapore who can advance their studies through our partnership with Molecular Genomics, which has been accelerating biodiscovery in Southeast Asia for more than a decade.”

About SomaLogic 
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

Forward Looking Statements Disclaimer 
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 

Media Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com

Investor Contacts
Lauren Glaser 
Lglaser@somalogic.com 


SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

THỦ THUẬT HAY

Những cách hạn chế tốc độ tải về của Microsoft Store

Đôi lúc, Microsoft Store cũng là một nhân tố ảnh hưởng rất xấu đến tốc độ mạng trên Windows 10. Dĩ nhiên, điều này cũng có thể được khắc chế với một vài thủ thuật đơn giản sau đây.

Giới thiệu về cơ sở dữ liệu - Database

Microsoft Access là công cụ tạo và quản lý cơ sở dữ liệu. Để hiểu về Access trước hết bạn phải hiểu về cơ sở dữ liệu (database).

Chỉ 5 phút để biến smartphone thành ‘máy chiếu 3D’

Để biến smartphone của bạn thành một máy chiếu 3D, bạn cần chuẩn bị những món đồ sau: giấy ô ly, hộp đĩa CD, bút, kéo, băng dính/ keo dán, dao dọc giấy và một chiếc smartphone.

Hướng dẫn bảo mật tài khoản Twitter nâng cao

Chắc chắn bạn đã sử dụng số điện thoại của mình để làm xác thực hai yếu cho tài khoản Twitter. Tuy nhiên, nếu bạn muốn đảm bảo an toàn thực sự tài khoản của mình, bạn nên xem xét việc tạo mật khẩu dành riêng cho ứng

Cài biểu tượng đồng hồ số trên màn hình chờ Windows 10

Khi chúng ta chưa tắt máy tính và không dùng, màn hình máy tính sau một thời gian theo thiết lập sẽ chuyển sang chế độ chờ. Trên chế độ này chúng ta có thể cho chạy ảnh hoặc các hiệu ứng khác, tuy nhiên bài viết này sẽ

ĐÁNH GIÁ NHANH

Test OPPO F3 Lite(A57): Chip Snapdragon 435 và 3GB RAM

OPPO F3 Lite (A57) là mẫu smartphone nhấn mạnh vào khả năng selfie tuyệt vời với camera trước 16MP, khẩu độ f/2.0. Đây cũng là smartphone tầm trung có hiệu năng tốt nhất của nhà sản xuất OPPO với chip Snapdragon 435 8

Đánh giá Kia Sorento 2016: Sang trọng và trẻ trung

AutoExpress - Kia Sorento 2016 gây được ấn tượng trong mắt người tiêu dùng và hứa hẹn tạo ra một làn sóng mới.

Đánh giá Camera của HTC U Ultra: Màu chuẩn, file RAW rất tốt... Điểm đánh giá: 8

Giao diện chụp thủ công của dòng One từ M8 trước đây là chuyên nghiệp nhất kể từ sau một vài dòng của Lumia. Hồi đó M8 bắt đầu hơi phức tạp việc chia ra cấp Auto - cấp thủ công một nửa